This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View
by Zacks Equity Research
Iovance (IOVA) reports better-than-expected second-quarter results. Shares price rises on the back of encouraging product revenue guidance issued by management for 2024 and 2025.
Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 0% and 26.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Allogene (ALLO) Posts Narrower Than Expected Loss in Q2
by Zacks Equity Research
Allogene's (ALLO) second-quarter earnings beat estimates but sales miss the mark. It expects to submit a regulatory filing with the FDA for its lead pipeline drug in large B-cell lymphoma indication by 2027.
Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak
by Zacks Equity Research
Sarepta (SRPT) reports mixed results in the second quarter. It issues revenue guidance for 2025, which is below expectations. Stock falls during after-market trading.
Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line
by Zacks Equity Research
Madrigal (MDGL) posts better than expected second-quarter numbers. It adds nearly $15 million from sales of the first-ever NASH drug Rezdiffra, which is encouraging for a drug launched in April 2024.
BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View
by Zacks Equity Research
BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
by Zacks Equity Research
Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.
Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View
by Zacks Equity Research
Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.
JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View
by Zacks Equity Research
Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 29.73% and 74.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.
Wall Street Analysts Predict a 54.95% Upside in Immatics (IMTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 55% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why 'Trend' Investors Would Love Betting on Immatics (IMTX)
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Immatics (IMTX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Stock Market News for May 15, 2024
by Zacks Equity Research
U.S. stocks closed higher on Tuesday as investors digested the key inflation data that heightened worries regarding inflation.
Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sangamo (SGMO) delivered earnings and revenue surprises of -22.73% and 94.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Absci (ABSI) Up on AstraZeneca Deal to Design New Cancer Therapy
by Zacks Equity Research
Absci (ABSI) announces a collaboration agreement with AstraZeneca to develop an AI-designed antibody for an undisclosed oncology target. The stock rises 13%.
Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)
by Zacks Equity Research
Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies
by Zacks Equity Research
The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.
How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%
by Zacks Equity Research
The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Immatics (IMTX) delivered earnings and revenue surprises of -2.94% and 28.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
ProQR (PRQR) delivered earnings and revenue surprises of 0% and 75.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Absci Corporation (ABSI) delivered earnings and revenue surprises of -8.33% and 41.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?